Loading
Extracellular Vesicles in Disease / Nanoplatforms for Cancer Theranostics · Journal article
Molecular Biomedicine · September 9, 2026
A consensus or society position rather than new primary data.
This is a narrative review of extracellular vesicle biology and therapeutic potential, not a report of original data or clinical trial results. It synthesizes current knowledge on EV-based approaches for cancer and immune disorders, identifies manufacturing and safety challenges, and recommends priorities for clinical translation, but does not provide evidence of efficacy or safety from controlled trials.
Journal article.
EVs are membrane-bound nano-sized particles serving as intercellular communication mediators, transporting proteins, lipids, nucleic acids, and metabolites within a protective lipid bilayer EVs originate from diverse sources including mammalian cells, plant cells, and bacteria EV characteristics valued for therapeutics include natural origin, intrinsic stability, low immunogenicity, and ability to cross biological barriers
No specific safety or immunogenicity data provided; challenges identified but not quantified Major challenges identified: scalable and standardized production, safety, and immunogenicity assessment
This review provides an overview of the EV therapeutic landscape and development pathway for clinicians and researchers to understand current capabilities and limitations. It does not provide evidence sufficient to guide treatment decisions and emphasizes that robust manufacturing protocols and comprehensive safety evaluations remain outstanding requirements before clinical deployment.
A comprehensive narrative review synthesizing the biology, engineering, and therapeutic potential of extracellular vesicles, offering expert perspective on current state and future directions rather than reporting original experimental results.
This review provides an overview of the EV therapeutic landscape and development pathway for clinicians and researchers to understand current capabilities and limitations. It does not provide evidence sufficient to guide treatment decisions and emphasizes that robust manufacturing protocols and comprehensive safety evaluations remain outstanding requirements before clinical deployment.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
Abstract Extracellular vesicles (EVs) are membrane-bound, nano-sized particles released by diverse cell types. They serve as key mediators of intercellular communication by transporting a broad repertoire of proteins, lipids, nucleic acids, and metabolites to recipient cells within a protective lipid bilayer. Owing to their natural origin, intrinsic stability, low immunogenicity, and ability to cross biological barriers, EVs are highly attractive candidates for next-generation therapeutics and drug delivery platforms. In this review, we summarize the biology of EVs and highlight the features critical for their application in therapeutic delivery. We trace their multiple origins, ranging from mammalian and plant cells to bacteria, underscoring their ubiquity across biological systems. We then analyze the advantages of EVs as next-generation delivery vehicles. From a practical standpoint, we examine current strategies for EV isolation, purification, characterization, and engineering. Importantly, we showcase several therapeutic applications of EVs for intractable diseases that are refractory to conventional approaches, such as cancer and immune disorders. We also discuss the major challenges on the path to clinical translation, particularly scalable and standardized production, as well as safety and immunogenicity. To fully realize the clinical potential of EV-based therapies, future research should prioritize the development of robust manufacturing protocols and comprehensive safety evaluations.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.